Shows the pointlessness of dividend investing, you’d get a better yield on risk free treasuries. Rio Tinto looking at cancelling its U.K. listing, the ftse is a dead man walking, much like the U.K. economy, 1970’s here we come, everyone blaming Labour and yes of course they are shxt, but the tories wrecked the joint, terrible politics, austerity, brexit, never recapitalised the banks properly, they have been a total disaster for the country and its currency and markets. |
TM - hope is not a strategy! |
Just keep accepting the dividends and wait for a sentiment change .... ;0) |
The only thing that makes sense would be to asset strip and the UK gov would never allow that |
Serious Fraud Office investigated company linked to ‘Chinese spy’.
Yang Tengbo was the director of business embroiled in allegations of foreign bribery involving drugs giant GlaxoSmithKline.
According to Tengbo, Hampton (Tengbo founded Hampton Group in 2005,) has worked with some of the UK's biggest companies with oeprations in China. He has claimed his work included helping high-end sports car manufacturer McClaren introduce its luxury road cars into China as well as saying his company advised GlaxoSmithKline as it was in the midst of a whistleblowing investigation. |
hTTps://moneyweek.com/investments/stocks-and-shares/five-stocks-for-new-year |
Well if the economists are to be believed the UK will grow by as much as 2% in 2025! |
With a Labour government wrecking the economy there's not much incentive for a Santa Rally ;0( |
So, does this make more sense?
Eli Lilly:
Mkt cap
739.16B
P/E ratio
84.10
Div yield
0.77% |
........but who would want the heavy infrastructure plus all that capitalised intangible? |
& hence why they're being snapped up one by one.
Eli Lilly market cap 770Bn.
GSK 50Bn
GSK is not too big to be bid for. |
Not many interested in UK stocks right now due to the time of the year / US sucking in all the cash.
Got to think that at some point the US unwinds a little and then can we get some fresh money / buyers??
Good luck all 👍🏻 |
8x P/E 2025
7x P/E 2026
Like so, so many UK stocks should be trading at a 50% premium. |
new ceo-new strategy and primary move to US. |
How come gsk get so much good news all the time at the moment and the share price is still so subdued? What on earth will it take for market sentiment to change? |
Because it is a British company and we need as many as possible to stay on the FTSE or you may whinge a little bit more when your taxes have to go up. |
Where in the world is GSK's most important revenue raising market - would that be the UK ?, No ?
Then why is it headquartered and listed here, for old times sake ?
Time for GSK to bunk off to pastures new ? |
 GSK plc (LSE/NYSE: GSK), a global biopharmaceutical company, announced today that the European Medicines Agency (EMA) has granted its investigational drug, GSK'227, the Priority Medicines (PRIME) designation for the treatment of relapsed extensive-stage small-cell lung cancer (ES-SCLC). This regulatory acknowledgment is based on early clinical data suggesting potential therapeutic benefits in a disease marked by limited treatment options and poor patient outcomes.
The PRIME designation is designed to expedite the development and review of drugs targeting unmet medical needs. GSK'227, an antibody-drug conjugate (ADC) targeting B7-H3, has shown promise in preliminary trials. It is the second major regulatory milestone for GSK'227, following the Breakthrough Therapy Designation it received from the US Food and Drug Administration in August 2024.
Senior Vice President of Global Head Oncology at GSK, Hesham Abdullah, remarked on the significance of this development, noting the potential of GSK'227 to improve treatment for ES-SCLC and other tumor types with limited therapeutic options. The PRIME designation was supported by data from the ARTEMIS-001 study, an ongoing phase I trial conducted by Hansoh Pharma, which assessed the drug's safety and efficacy in over 200 patients with various advanced solid tumors.
Lung cancer remains one of the leading causes of cancer-related deaths globally. In Europe alone, lung cancer accounted for an estimated 484,554 new cases and 375,784 deaths in 2022. ES-SCLC, a particularly aggressive form of lung cancer, often presents with widespread disease at diagnosis and has a high rate of relapse after initial treatment. |
More tax, more wasted, more then needed as growth craters further.Most inept government in history |
Good time to invest in large uk headquartered multi national companies.Gsk is a great buy. |
Confidence in the UK markets is so low that nobody wants to invest here.
And now there is talk of an emergency tax raising budget in the spring.
God help us.
Suet |
And back below 1300 we go |
Register for real-time alerts, custom portfolio, and market movers
Hot Features
Premium
